Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) continues its growth following the build of a new 50,000 sq ft GMP manufacturing facility and recent sterile fill-finish capability announcement, with the appointment of Philip Payne as Chief Commercial Officer (CCO).
Philip joins Upperton’s leadership team and Board, following recent investment in the company’s marketing and sales infrastructure.
Philip will work with Upperton’s leadership team and Board to drive the commercial strategy, leading the sales and marketing function and helping to guide the next stage of Upperton’s growth, including identification of new geographies and markets, supporting the continued growth of Upperton’s service offering into Europe and the US.
Philip has extensive experience in managing the integration of business development in an international environment across discovery, development and manufacturing.
He joins Upperton following senior commercial roles at global pharmaceutical services companies including Abzena, Concept Life Sciences, Aptuit and Catalent Pharma Solutions.
Philip said, “I am delighted to be joining Upperton. The company truly has a unique customer and focused culture that immediately made an impression. I look forward to working with the team to bring Upperton’s approach and experience to customers.”
Nikki Whitfield, CEO of Upperton Pharma Solutions, said, “Philip’s industry experience will be a great asset as we continue our expansion into new markets. He is a strong addition to our leadership team, providing strategic knowledge that will support our growth.”
Article provided by Medilink Midlands Member Upperton Pharma Solutions, find out more here.